TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Protocol For a Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Celecoxib (SC-58635) In The Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP)
Brief Summary: This study is a prospective, randomized, double-blind, placebo-controlled, multi-center trial to compare the efficacy and safety of celecoxib 400mg QD versus placebo in reducing the occurrence of new colorectal adenomas post-polypectomy at Month 13 (Year 1) and Month 37 (Year 3) of study drug administration.


Options:
A: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Celecoxib | Intervention Type: DRUG; Name: Celecoxib; Assigned to Arm(s): A
B: Intervention Type: DRUG; Name: indomethacin; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Celecoxib (Celebrex); Assigned to Arm(s): N/A
D: Arm Label: Aggrenox, Clopidogrel placebo, Micardis; Type: PLACEBO_COMPARATOR; Interventions: Drug: Aggrenox, Drug: Clopidogrel placebo, Drug: Micardis | Arm Label: Aggrenox placebo, clopidogrel,, Micardis; Type: PLACEBO_COMPARATOR; Interventions: Drug: Micardis, Drug: Aggrenox placebo, Drug: Clopidogrel | Arm Label: Aggrenox, clop placebo, micardis placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Aggrenox, Drug: Clopidogrel placebo, Drug: Micardis placebo | Arm Label: Aggrenox plcebo, clop, micardis placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Aggrenox placebo, Drug: Clopidogrel, Drug: Micardis placebo | Intervention Type: DRUG; Name: Aggrenox; Assigned to Arm(s): Aggrenox, Clopidogrel placebo, Micardis | Intervention Type: DRUG; Name: Aggrenox; Assigned to Arm(s): Aggrenox, clop placebo, micardis placebo | Intervention Type: DRUG; Name: Clopidogrel placebo; Assigned to Arm(s): Aggrenox, Clopidogrel placebo, Micardis | Intervention Type: DRUG; Name: Clopidogrel placebo; Assigned to Arm(s): Aggrenox, clop placebo, micardis placebo | Intervention Type: DRUG; Name: Micardis; Assigned to Arm(s): Aggrenox, Clopidogrel placebo, Micardis | Intervention Type: DRUG; Name: Micardis; Assigned to Arm(s): Aggrenox placebo, clopidogrel,, Micardis | Intervention Type: DRUG; Name: Aggrenox placebo; Assigned to Arm(s): Aggrenox placebo, clopidogrel,, Micardis | Intervention Type: DRUG; Name: Aggrenox placebo; Assigned to Arm(s): Aggrenox plcebo, clop, micardis placebo | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Aggrenox placebo, clopidogrel,, Micardis | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Aggrenox plcebo, clop, micardis placebo | Intervention Type: DRUG; Name: Micardis placebo; Assigned to Arm(s): Aggrenox, clop placebo, micardis placebo | Intervention Type: DRUG; Name: Micardis placebo; Assigned to Arm(s): Aggrenox plcebo, clop, micardis placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Protocol For a Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Celecoxib (SC-58635) In The Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP)
Brief Summary: This study is a prospective, randomized, double-blind, placebo-controlled, multi-center trial to compare the efficacy and safety of celecoxib 400mg QD versus placebo in reducing the occurrence of new colorectal adenomas post-polypectomy at Month 13 (Year 1) and Month 37 (Year 3) of study drug administration.


Options:
A: Arm Label: Arm I (celecoxib); Type: EXPERIMENTAL; Interventions: Drug: celecoxib | Arm Label: Arm II (placebo); Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: celecoxib; Assigned to Arm(s): Arm I (celecoxib) | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm II (placebo)
B: Arm Label: Arm I (celecoxib); Type: EXPERIMENTAL; Interventions: Drug: Celecoxib, Other: Laboratory Biomarker Analysis | Arm Label: Arm II (placebo); Type: PLACEBO_COMPARATOR; Interventions: Other: Laboratory Biomarker Analysis, Other: Placebo | Intervention Type: DRUG; Name: Celecoxib; Assigned to Arm(s): Arm I (celecoxib) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (celecoxib), Arm II (placebo) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm II (placebo)
C: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Celecoxib | Intervention Type: DRUG; Name: Celecoxib; Assigned to Arm(s): A
D: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix™ | Arm Label: Havrix Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Havrix™-based investigational formulation | Intervention Type: BIOLOGICAL; Name: Cervarix™; Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Havrix™-based investigational formulation; Assigned to Arm(s): Havrix Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study With Follow-up Evaluating the Safety and Efficacy of Varenicline Tartrate ( CP-526,555) in Comparison to Zyban for Smoking Cessation
Brief Summary: The primary purpose of this study is to evaluate the safety and efficacy of varenicline given for a twelve week treatment period in comparison with placebo and Zyban for smoking cessation.


Options:
A: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
B: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Champix; Type: EXPERIMENTAL; Interventions: Drug: Champix | Arm Label: Long & Combination patch treatment; Type: EXPERIMENTAL; Interventions: Drug: Transdermal Nicoderm patch combined with gum or inhaler | Arm Label: Standard patch treatment; Type: EXPERIMENTAL; Interventions: Drug: Transdermal Nicoderm patch | Intervention Type: DRUG; Name: Champix; Assigned to Arm(s): Champix | Intervention Type: DRUG; Name: Transdermal Nicoderm patch combined with gum or inhaler; Assigned to Arm(s): Long & Combination patch treatment | Intervention Type: DRUG; Name: Transdermal Nicoderm patch; Assigned to Arm(s): Standard patch treatment
D: Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study With Follow-up Evaluating the Safety and Efficacy of Varenicline Tartrate ( CP-526,555) in Comparison to Zyban for Smoking Cessation
Brief Summary: The primary purpose of this study is to evaluate the safety and efficacy of varenicline given for a twelve week treatment period in comparison with placebo and Zyban for smoking cessation.


Options:
A: Arm Label: 1 - CBT Counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Motivational interviewing for smoking cessation, Behavioral: Cognitive behaviors therapy | Arm Label: 2 - Counseling + NRT; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational interviewing for smoking cessation, Drug: CBT + NRT | Intervention Type: BEHAVIORAL; Name: Motivational interviewing for smoking cessation; Assigned to Arm(s): 1 - CBT Counseling, 2 - Counseling + NRT | Intervention Type: BEHAVIORAL; Name: Cognitive behaviors therapy; Assigned to Arm(s): 1 - CBT Counseling | Intervention Type: DRUG; Name: CBT + NRT; Assigned to Arm(s): 2 - Counseling + NRT
B: Arm Label: E-Cigarette 7.2 mg nicotine; Type: EXPERIMENTAL; Interventions: Device: E-Cigarette 7.2 mg nicotine | Intervention Type: DEVICE; Name: E-Cigarette 7.2 mg nicotine; Assigned to Arm(s): E-Cigarette 7.2 mg nicotine
C: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
D: Arm Label: Nicotrol Inhaler; Type: EXPERIMENTAL; Interventions: Drug: Nicotrol Inhaler | Arm Label: Placebo Inhaler; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Inhaler | Intervention Type: DRUG; Name: Nicotrol Inhaler; Assigned to Arm(s): Nicotrol Inhaler | Intervention Type: DRUG; Name: Placebo Inhaler; Assigned to Arm(s): Placebo Inhaler

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study With Follow-up Evaluating the Safety and Efficacy of Varenicline Tartrate ( CP-526,555) in Comparison to Zyban for Smoking Cessation
Brief Summary: The primary purpose of this study is to evaluate the safety and efficacy of varenicline given for a twelve week treatment period in comparison with placebo and Zyban for smoking cessation.


Options:
A: Arm Label: Ecig 24 mg nicotine; Type: EXPERIMENTAL; Interventions: Device: Ecig 24 mg nicotine | Arm Label: Ecig 0 mg nicotine; Type: SHAM_COMPARATOR; Interventions: Device: Ecig 0 mg nicotine | Arm Label: Nicotine free inhalator; Type: PLACEBO_COMPARATOR; Interventions: Device: Nicotine free inhalator | Intervention Type: DEVICE; Name: Ecig 24 mg nicotine; Assigned to Arm(s): Ecig 24 mg nicotine | Intervention Type: DEVICE; Name: Ecig 0 mg nicotine; Assigned to Arm(s): Ecig 0 mg nicotine | Intervention Type: DEVICE; Name: Nicotine free inhalator; Assigned to Arm(s): Nicotine free inhalator
B: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline(Chantix) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline(Chantix); Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Extended Varenicline Pretreatment; Type: EXPERIMENTAL; Interventions: Drug: Extended Varenicline Pretreatment | Arm Label: Short-term Varenicline Pretreatment; Type: EXPERIMENTAL; Interventions: Drug: Short-term Varenicline Pretreatment | Intervention Type: DRUG; Name: Extended Varenicline Pretreatment; Assigned to Arm(s): Extended Varenicline Pretreatment | Intervention Type: DRUG; Name: Short-term Varenicline Pretreatment; Assigned to Arm(s): Short-term Varenicline Pretreatment
D: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study With Follow-up Evaluating the Safety and Efficacy of Varenicline Tartrate ( CP-526,555) in Comparison to Zyban for Smoking Cessation
Brief Summary: The primary purpose of this study is to evaluate the safety and efficacy of varenicline given for a twelve week treatment period in comparison with placebo and Zyban for smoking cessation.


Options:
A: Arm Label: Bupropion and Weight Concerns intervention; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Behavioral: weight concerns intervention | Arm Label: Placebo and Weight Concerns; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Behavioral: weight concerns intervention | Arm Label: Bupropion and standard smoking cessation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion, Behavioral: smoking cessation intervention | Arm Label: Placebo and standard smoking cessation; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: smoking cessation intervention | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Bupropion and Weight Concerns intervention, Bupropion and standard smoking cessation | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo and Weight Concerns, Placebo and standard smoking cessation | Intervention Type: BEHAVIORAL; Name: weight concerns intervention; Assigned to Arm(s): Bupropion and Weight Concerns intervention, Placebo and Weight Concerns | Intervention Type: BEHAVIORAL; Name: smoking cessation intervention; Assigned to Arm(s): Bupropion and standard smoking cessation, Placebo and standard smoking cessation
B: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
C: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo tablet is made of lactose | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo tablet is made of lactose; Assigned to Arm(s): control group
D: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Nicotine Patches only; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches | Arm Label: Nicotine Patches with Nicotine Inhaler; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches, Drug: Nicotine Inhaler | Arm Label: varenicline with bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Drug: Bupropion | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline, varenicline with bupropion | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): varenicline with bupropion | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Nicotine Patches only, Nicotine Patches with Nicotine Inhaler | Intervention Type: DRUG; Name: Nicotine Inhaler; Assigned to Arm(s): Nicotine Patches with Nicotine Inhaler

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study With Follow-up Evaluating the Safety and Efficacy of Varenicline Tartrate ( CP-526,555) in Comparison to Zyban for Smoking Cessation
Brief Summary: The primary purpose of this study is to evaluate the safety and efficacy of varenicline given for a twelve week treatment period in comparison with placebo and Zyban for smoking cessation.


Options:
A: Arm Label: Healthy Control - Non-smoking; Type: OTHER; Interventions: Other: Biological Control | Arm Label: Healthy Control - Smoker; Type: OTHER; Interventions: Other: Biological Control | Arm Label: HIV Smoking Cessation Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline tartrate, Drug: Nicotine Replacement Therapy | Arm Label: Motivational Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interview | Intervention Type: DRUG; Name: Varenicline tartrate; Assigned to Arm(s): HIV Smoking Cessation Arm | Intervention Type: DRUG; Name: Nicotine Replacement Therapy; Assigned to Arm(s): HIV Smoking Cessation Arm | Intervention Type: OTHER; Name: Biological Control; Assigned to Arm(s): Healthy Control - Non-smoking, Healthy Control - Smoker | Intervention Type: BEHAVIORAL; Name: Motivational Interview; Assigned to Arm(s): Motivational Intervention
B: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: IQOS; Type: EXPERIMENTAL; Interventions: Device: IQOS | Arm Label: E-CIG; Type: ACTIVE_COMPARATOR; Interventions: Device: E-CIG | Intervention Type: DEVICE; Name: IQOS; Assigned to Arm(s): IQOS | Intervention Type: DEVICE; Name: E-CIG; Assigned to Arm(s): E-CIG

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study With Follow-up Evaluating the Safety and Efficacy of Varenicline Tartrate ( CP-526,555) in Comparison to Zyban for Smoking Cessation
Brief Summary: The primary purpose of this study is to evaluate the safety and efficacy of varenicline given for a twelve week treatment period in comparison with placebo and Zyban for smoking cessation.


Options:
A: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
B: Arm Label: P; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion HCl ER | Intervention Type: DRUG; Name: Bupropion HCl ER; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): P
C: Arm Label: Group I (varenicline and placebo); Type: EXPERIMENTAL; Interventions: Other: Placebo, Other: Tobacco Cessation Counseling, Drug: Varenicline | Arm Label: Group II (placebo, nicotine patch and lozenge); Type: PLACEBO_COMPARATOR; Interventions: Drug: Nicotine Lozenge, Drug: Nicotine Patch, Other: Placebo, Other: Tobacco Cessation Counseling | Intervention Type: DRUG; Name: Nicotine Lozenge; Assigned to Arm(s): Group II (placebo, nicotine patch and lozenge) | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Group II (placebo, nicotine patch and lozenge) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Group I (varenicline and placebo), Group II (placebo, nicotine patch and lozenge) | Intervention Type: OTHER; Name: Tobacco Cessation Counseling; Assigned to Arm(s): Group I (varenicline and placebo), Group II (placebo, nicotine patch and lozenge) | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Group I (varenicline and placebo)
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: 300 mg/day bupropion-sr | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0 mg/day bupropion-sr | Intervention Type: DRUG; Name: 300 mg/day bupropion-sr; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: 0 mg/day bupropion-sr; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study With Follow-up Evaluating the Safety and Efficacy of Varenicline Tartrate ( CP-526,555) in Comparison to Zyban for Smoking Cessation
Brief Summary: The primary purpose of this study is to evaluate the safety and efficacy of varenicline given for a twelve week treatment period in comparison with placebo and Zyban for smoking cessation.


Options:
A: Arm Label: Control arm; Type: ACTIVE_COMPARATOR; Interventions: Other: Control arm (i.e: regular care) | Arm Label: Intervention arm; Type: EXPERIMENTAL; Interventions: Behavioral: Pharmacist delivered smoking cessation program | Intervention Type: BEHAVIORAL; Name: Pharmacist delivered smoking cessation program; Assigned to Arm(s): Intervention arm | Intervention Type: OTHER; Name: Control arm (i.e: regular care); Assigned to Arm(s): Control arm
B: Arm Label: CPT+ICSC; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Processing Therapy (CPT), Drug: Bupropion, Drug: nicotine replacement therapy (NRT), Behavioral: Integrated Care for Smoking Cessation (ICSC), Behavioral: smokefreeVET | Arm Label: ICSC only; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion, Drug: nicotine replacement therapy (NRT), Behavioral: Integrated Care for Smoking Cessation (ICSC), Behavioral: smokefreeVET | Intervention Type: BEHAVIORAL; Name: Cognitive Processing Therapy (CPT); Assigned to Arm(s): CPT+ICSC | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): CPT+ICSC, ICSC only | Intervention Type: DRUG; Name: nicotine replacement therapy (NRT); Assigned to Arm(s): CPT+ICSC, ICSC only | Intervention Type: BEHAVIORAL; Name: Integrated Care for Smoking Cessation (ICSC); Assigned to Arm(s): CPT+ICSC, ICSC only | Intervention Type: BEHAVIORAL; Name: smokefreeVET; Assigned to Arm(s): CPT+ICSC, ICSC only
C: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
D: Arm Label: Randomized Phase: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Randomized Phase: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Randomized Phase: Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Randomized Phase: Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study With Follow-up Evaluating the Safety and Efficacy of Varenicline Tartrate ( CP-526,555) in Comparison to Zyban for Smoking Cessation
Brief Summary: The primary purpose of this study is to evaluate the safety and efficacy of varenicline given for a twelve week treatment period in comparison with placebo and Zyban for smoking cessation.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
C: Arm Label: NicVAX conjugate vaccine; Type: EXPERIMENTAL; Interventions: Biological: NicVAX vaccine, Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Drug: Varenicline | Intervention Type: BIOLOGICAL; Name: NicVAX vaccine; Assigned to Arm(s): NicVAX conjugate vaccine | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): NicVAX conjugate vaccine, Placebo
D: Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study With Follow-up Evaluating the Safety and Efficacy of Varenicline Tartrate ( CP-526,555) in Comparison to Zyban for Smoking Cessation
Brief Summary: The primary purpose of this study is to evaluate the safety and efficacy of varenicline given for a twelve week treatment period in comparison with placebo and Zyban for smoking cessation.


Options:
A: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
C: Arm Label: Extended Patch Treatment; Type: EXPERIMENTAL; Interventions: Drug: 24-weeks of nicotine patch | Arm Label: Standard Patch Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Patch Treatment | Intervention Type: DRUG; Name: Standard Patch Treatment; Assigned to Arm(s): Standard Patch Treatment | Intervention Type: DRUG; Name: 24-weeks of nicotine patch; Assigned to Arm(s): Extended Patch Treatment
D: Arm Label: Placebo (Slow Metabolizers); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Varenicline (Slow Metabolizers); Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Transdermal Nicotine (Slow Metabolizers); Type: ACTIVE_COMPARATOR; Interventions: Drug: Transdermal Nicotine | Arm Label: Placebo (Normal Metabolizers); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Varenicline (Normal Metabolizers); Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Transdermal Nicotine (Normal Metabolizers); Type: ACTIVE_COMPARATOR; Interventions: Drug: Transdermal Nicotine | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline (Normal Metabolizers), Varenicline (Slow Metabolizers) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (Normal Metabolizers), Placebo (Slow Metabolizers) | Intervention Type: DRUG; Name: Transdermal Nicotine; Assigned to Arm(s): Transdermal Nicotine (Normal Metabolizers), Transdermal Nicotine (Slow Metabolizers)

Answer: B